<DOC>
	<DOC>NCT02524782</DOC>
	<brief_summary>A Phase 1, combined Single Ascending Dose (SAD) and Multiple-ascending Dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MEDI4166 in Subjects with Type 2 Diabetes Mellitus (T2D).</brief_summary>
	<brief_title>A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>This study is a first time in human (FTIH), Phase 1, randomized, double-blind study to evaluate the safety, tolerability, PK, and PD of MEDI4166 administered as both single and multiple ascending doses to subjects with T2D.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 Diabetes, ages 1865 Must provide written informed consent BMI&gt;=25 and =&lt;42 Venous access suitable for multiple cannulations Vital signs within normal specified ranges Females must be nonlactating and nonchildbearing potential Males must practice 2 effective contraceptive measures if sexually active Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs History of cancer, with the exception of basal cell carcinoma or carcinoma of the cervix Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing Positive Hepatitis B, Hepatitis C or HIV test or use of antiretroviral medications at screening Current or previous use of systemic corticosteroids within the past 28 days prior to screening Use of any medicinal products or herbal preparations licensed for weight loss is prohibited. Positive drug screen Type 1 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MEDI-4166, diabetes</keyword>
</DOC>